<DOC>
	<DOCNO>NCT00110929</DOCNO>
	<brief_summary>The purpose research study efficacy safety AMG 073 patient kidney failure treat hemodialysis peritoneal dialysis also secondary hyperparathyroidism ( HPT ) .</brief_summary>
	<brief_title>Treatment Patients With Secondary Hyperparathyroidism End-Stage Renal Disease ( ESRD )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Completed one qualify study ( i.e. , patient previously take part Amgen study investigate drug AMG 073 effect secondary hyperparathyroidism [ HPT ] ; particular parathyroid hormone [ PTH ] , calcium phosphorus level blood associate kidney failure ) Must agree use , opinion principal investigator , highly effective contraceptive measure throughout study Pregnant nursing female Experienced myocardial infarction within 3 month day 1 Have unstable medical condition , define hospitalize , dialysis vascular access revision , within 30 day day 1 , otherwise unstable judgment investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Sensipar®</keyword>
	<keyword>Secondary HPT</keyword>
	<keyword>Mimpara®</keyword>
	<keyword>Cinacalcet</keyword>
	<keyword>calcimimetic</keyword>
	<keyword>End-Stage Renal Disease ( ESRD )</keyword>
</DOC>